COVID-19 hit the world hard. It impacted on everyone’s lives and overwhelmed healthcare resources worldwide, which lead to deaths that could have been prevented. On the individual level, it was difficult for people to know what was happening, how to prepare and behave, when to seek medical help and what to do post-COVID-19.
DRAGON is an Innovative Medicines Initiative (IMI) project which started on 1 October 2020, in the middle of the 2nd wave of the COVID-19 pandemic, and ran for 3 years. The project was coordinated by the University of Maastricht with Radiomics as the Project Lead. The partners include high-tech, small and medium sized enterprises, academic research institutes, biotechnology partners , together with the patient centered organization, European Lung Foundation (ELF) and professional society, European Respiratory Society (ERS).
DRAGON is built on the ambition to increase the capacity of health systems, speed up the pace of research and innovation, and empower citizens during a pandemic if we:
• improve how we diagnose people
• are able to predict patient outcomes early on
• empower citizens and patients to participate in their diagnosis as well as care and research
DRAGON uses advanced approaches such as:
• artificial intelligence (AI) – algorithms that learn and improve when they are provided with new information
• patient and doctor decision support tools in the form of personal health applications (apps)
• molecular profiling (a way of classifying a condition or disease outcome based of its genetic and other biomarkers)
These approaches will help to increase healthcare capacity and enable the research and innovation process by making them more efficient and provide patients and the public with tools to help and guide them during a pandemic.